Relapsed Prostate Cancer Clinical Trial
Official title:
Prospective Evaluation of 68-Ga-PSMA -PET and Early PSA Kinetics During Salvage Radiotherapy for Personalizing the Management of Men With Relapse of Prostate Cancer After Radical Prostatectomy
This is an open-label, phase II trial in patients with PSA recurrence after prostatectomy.
Patients entering the study will all receive initial 50 Gray (Gy) radiotherapy (25 x 2Gy) to
the prostate bed and thereafter be classified as either responders or non-responders
depending on PSA response at fifth week of radiotherapy.
A 68-Ga- PSMA-PET is done before start of radiotherapy, and analyzed before fifth treatment
week in order to identify cancer lesions in patients with poor PSA response. Patients with
PSA response after 5 weeks of radiotherapy will not receive any subsequent therapy, whilst
patients with poor PSA response may be in need for additional therapy such as radiotherapy to
lymph node metastases and/or boost fractions to local recurrence. Patients with more than 3
lymph node metastases or distant metastases will not receive any more radiotherapy, but
individualized systemic therapy will be started.
n/a